Searcharxiv⌕ Search
Home/Archive/arXiv

arXiv · q-bio/0512022

Mathematical modeling of anti-tumor virus therapy: Regimes with complete recovery within the framework of deterministic models

Artem S. Novozhilov·Faina S. Berezovskaya·Eugene V. Koonin·Georgy P. Karev
View original source ↗Read source document ↗Export metadata ↓

Abstract

A complete parametric analysis of dynamic regimes of a conceptual model of anti-tumor virus therapy is presented. The role and limitations of mass-action kinetics are discussed. A functional response, which is a function of the ratio of uninfected to infected tumor cells, is proposed to describe the spread of the virus infection in the tumor. One of the main mathematical features of ratio-dependent models is that the origin is a complicated equilibrium point whose characteristics crucially determine the main properties of the model. It is shown that, in a certain area of parameter values, the trajectories of the model form a family of homoclinics to the origin (so-called elliptic sector). Biologically, this means that both infected and uninfected tumor cells can be eliminated with time, and complete recovery is possible as a result of the virus therapy within the framework of deterministic models

Explore related subjects

q-bio.TOq-bio.PE

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Artem S. Novozhilov, Faina S. Berezovskaya, Eugene V. Koonin, Georgy P. Karev. 2005-12-09. Mathematical modeling of anti-tumor virus therapy: Regimes with complete recovery within the framework of deterministic models. https://arxiv.org/abs/q-bio/0512022

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related papers

arXiv2026

A senescent-immune reserve niche hypothesis for incomplete lobular involution in the aging breast

Breast cancer incidence rises with age and peaks across the menopausal transition, yet why some postmenopausal lobules persist, and why that persistence predicts cancer risk, remains unresolved. Incomplete age-related lobular involution is one of the strongest tissue-level predictors of subsequent breast cancer, but it is still commonly viewed as passive failure of hormonally driven regression. This Review proposes a different framework: persistent lobules are maintained by an active reserve niche that outlasts its reproductive function. Recent human tissue studies show that persistent postmenopausal lobules retain a proliferation-competent epithelial state and that immune cells accumulate at the lobular boundary without being positioned to engage p16INK4a-positive epithelial foci; in a separate longitudinal cohort, senescence-linked programs reverse their association with involution pace across menopause. We integrate these findings with breast epidemiology and mammary stromal biology, and draw on reserve systems in skeletal muscle, hematopoiesis, and postmenopausal endometrium as sources of candidate mechanisms and testable predictions rather than as evidence for the breast. We argue that menopause is a biological control point at which tissue fate diverges, and that what distinguishes persistence from resolution is not the amount of inflammation present but whether immune effectors are spatially positioned to execute clearance. This shifts attention from epithelial quantity to microenvironmental state and identifies the perimenopausal window as a promising interval for biomarker-guided risk stratification and prevention.

q-bio.TO↗
arXiv2026

retinalysis-vascx: An explainable software toolbox for the extraction of retinal vascular biomarkers

Automatic extraction of retinal vascular biomarkers from color fundus images (CFI) is crucial for large-scale studies of the retinal vasculature. We present VascX, an open-source Python toolbox that extracts biomarkers from CFI artery-vein segmentations. VascX starts from vessel segmentation masks, extracts their skeletons, builds undirected and directed vessel graphs, and resolves vessel segments into longer vessels. A comprehensive set of biomarkers is derived, including vascular density, central retinal equivalents (CREs), and tortuosity. Spatially localized biomarkers may be calculated over grids placed relative to the fovea and optic disc. VascX is released via GitHub and PyPI with comprehensive documentation and examples. Our test-retest reproducibility analysis on repeat imaging of the same eye by different devices shows that most VascX biomarkers have moderate to excellent agreement (ICC > 0.5), with important differences in the level of robustness of different biomarkers. Our analyses of biomarker sensitivity to image perturbations and heuristic parameter values support these differences and further characterize VascX biomarkers. Ultimately, VascX provides an explainable and easily modifiable feature-extraction toolbox that complements segmentation to produce reliable retinal vascular biomarkers. Our graph-based biomarker computation stages support reproducible, region-aware measurements suited for large-scale clinical and epidemiological research. By enabling easy extraction of existing biomarkers and rapid experimentation with new ones, VascX supports oculomics research. Its robustness and computational efficiency facilitate scalable deployment in large databases, while open-source distribution lowers barriers to adoption for ophthalmic researchers and clinicians.

q-bio.TO↗
arXiv2026

Adaptive therapy under parametric, structural, and measurement uncertainty

Adaptive therapy has emerged as a promising treatment strategy that exploits within-tumour competition to delay disease progression. Implementation, however, typically relies on indirect measurements of tumour burden and must account for potentially substantial patient heterogeneity. In this work, we capture patient-to-patient variability, parameter uncertainty, and imperfect biomarker measurements with a mathematical and statistical model that we calibrate to clinical prostate cancer data using a Bayesian inference framework. We use the resulting virtual cohort to demonstrate that, within the simple but now well-established Lotka-Volterra-based model, adaptive therapy robustly improves time-to-progression for the subset of patients that are predicted to eventually progress by the model. To account for other risk factors associated with larger tumour volumes, we introduce a new metric based on the risk of metastasis that demonstrates how adaptive therapy may be disadvantageous when sustained tumour burden is also considered. Given the ubiquity of uncertainty in oncology, we then describe several future modelling directions that also capture uncertainty in the temporal evolution of the underlying tumour or biomarker dynamics. Finally, we demonstrate how model misspecification and non-identifiability can lead to unreliable predictions, especially if uncertainty is inadequately captured.

q-bio.TO↗